Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells

Blood

Volumn 99, Issue 9, 2002, Pages 3169-3178

  Leimig, Thasia ^a   Mann, Linda ^a   Martin, Maria Del Pilar ^a   Bonten, Erik ^a   Persons, Derek ^a   Knowles, James ^a   Allay, James A ^a   Cunningham, John ^a   Nienhuis, Arthur W ^a   Smeyne, Richard ^a   D'Azzo, Alessandra ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GREEN FLUORESCENT PROTEIN; PROTECTIVE PROTEIN CATHEPSIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BONE MARROW; BRAIN; CELL COUNT; CELLULAR DISTRIBUTION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DNA MODIFICATION; ENZYME ACTIVITY; FOLLOW UP; GALACTOSIALIDOSIS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LIVER; LUNG; LYSOSOME; MOUSE; MURINE STEM CELL VIRUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; PURKINJE CELL; SPLEEN; THYMUS; TREATMENT OUTCOME; VIRUS;

EID: 0036566195     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.9.3169     Document Type: Article

References (48)

1. Lysosomal storage diseases
2. Galactosialidosis
3. Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man
4. Expression of cDNA encoding the human "protective protein" associated with lysosomal beta-galactosidase and neuraminidase: Homology to yeast proteases
5. Early infantile galactosialidosis: Clinical, biochemical, and molecular observations in a new patient
6. Gene transfer approaches to the lysosomal storage disorders
7. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer
8. Allogeneic bone marrow transplantation for lysosomal storage disorders
9. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome
10. Targeting gene products to the brain and neurons using bone marrow transplantation: A cell-mediated delivery system for therapy of inherited metabolic human disease
11. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type Ill
12. Bone marrow transplantation therapy for metabolic disease: Animal models as predictors of success and in utero approaches
13. Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells
14. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation
15. Lack of PPCA expression does not always correlate with lysosomal storage: A possible requirement for the catalytic function of PPCA in galactosialidosis
16. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter
17. A safe packaging cell line for gene transfer. Separating viral genes on different plasmids
18. Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy
19. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site
20. Versatile retroviral vectors for potential use in gene therapy
21. Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis
22. Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells
23. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo
24. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function
25. An immunochemical analysis of the distribution of a brain-specific polypeptide, PEP-19
26. Purkinje cell loss is due to a direct action of the weaver gene in Purkinje cells: Evidence from chimeric mice
27. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII
28. Niemann-Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation
29. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice
30. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates
31. Autologous transplantation of retrovirally transduced bone marrow or neonatal blood cells into cats can lead to long-term engraftment in the absence of myeloablation
32. Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice
33. Bone marrow transplantation and gene therapy for lysosomal storage diseases
34. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo
35. The control of IL-4 gene expression in activated murine T lymphocytes
36. Humoral immune response limits gene therapy in canine MPS I
37. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells
38. Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy
39. Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector
40. In utero transplantation of fetal liver cells in the mucopolysaccharidosis type VII mouse results in low-level chimerism, but overexpression of beta-glucuronidase can delay onset of clinical signs
41. Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency
42. Dynamic analysis of proviral induction and de novo methylation: Implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression
43. Beyond the nucleosome: Epigenetic aspects of position-effect variegation in Drosophila
44. Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells
45. A functional enhancer suppresses silencing of a transgene and prevents its localization close to centrometric heterochromatin
46. Bone marrow transplantation in acid sphingomyelinase-deficient mice: Engraftment and cell migration into the brain as a function of radiation, age, and phenotype
47. Hematopoietic stem cell gene therapy for Niemann-Pick disease and other lysosomal storage diseases